0B68 Brody, Jonathan - Thomas Jefferson University - Thomas Jefferson University
jrb006

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Room 623
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  2. Novel targets in pancreatic cancer research
  3. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: Native ribonucleoprotein immunoprecipitation (RIP) assays
  4. MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer
  5. Upgrading gemcitabine with recycled kinase inhibitors
  6. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types
  7. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  8. Commentary : Fusing transcriptomics to progressive prostate cancer
  9. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  10. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial
  11. PARP inhibitors for chemoprevention - Letter
  12. Structural implications for selective targeting of PARPs
  13. Targeting cell cycle and hormone receptor pathways in cancer
  14. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
  15. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer
  16. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer
  17. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
  18. Dual roles of PARP-1 promote cancer growth and progression
  19. Pancreatic cancer and premalignant tumors: Molecular aspects
  20. Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box"
0